CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 4.5%

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) were up 4.5% during mid-day trading on Tuesday . The stock traded as high as $58.68 and last traded at $58.15. Approximately 391,733 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 1,814,702 shares. The stock had previously closed at $55.66.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CRSP shares. Royal Bank of Canada boosted their price objective on CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a report on Thursday, February 22nd. Morgan Stanley upped their price target on CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a report on Monday, February 26th. Chardan Capital upped their price target on CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price target on shares of CRISPR Therapeutics in a report on Thursday, April 11th. Finally, TheStreet raised CRISPR Therapeutics from a “d+” rating to a “c” rating in a report on Friday, February 23rd. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $76.29.

CRISPR Therapeutics Stock Up 2.7 %

The business has a 50-day moving average price of $72.54 and a 200-day moving average price of $63.76. The firm has a market capitalization of $4.85 billion, a PE ratio of -29.01 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million during the quarter, compared to analysts’ expectations of $148.72 million. CRISPR Therapeutics’s revenue for the quarter was up 3253.3% on a year-over-year basis. During the same quarter last year, the company earned ($1.41) earnings per share. On average, equities research analysts anticipate that CRISPR Therapeutics AG will post -6.24 earnings per share for the current year.

Insider Activity

In related news, CEO Samarth Kulkarni sold 20,000 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $80.36, for a total value of $1,607,200.00. Following the completion of the transaction, the chief executive officer now directly owns 187,377 shares in the company, valued at $15,057,615.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Raju Prasad sold 3,524 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $72.69, for a total value of $256,159.56. Following the transaction, the chief financial officer now owns 6,476 shares of the company’s stock, valued at $470,740.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Samarth Kulkarni sold 20,000 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $80.36, for a total value of $1,607,200.00. Following the completion of the transaction, the chief executive officer now directly owns 187,377 shares in the company, valued at approximately $15,057,615.72. The disclosure for this sale can be found here. Insiders sold 133,992 shares of company stock worth $9,157,835 over the last ninety days. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Several large investors have recently bought and sold shares of the business. National Bank of Canada FI grew its holdings in shares of CRISPR Therapeutics by 31.9% during the third quarter. National Bank of Canada FI now owns 1,838 shares of the company’s stock worth $78,000 after buying an additional 445 shares during the last quarter. CWM LLC grew its holdings in shares of CRISPR Therapeutics by 80.7% during the third quarter. CWM LLC now owns 582 shares of the company’s stock worth $26,000 after buying an additional 260 shares during the last quarter. Leavell Investment Management Inc. acquired a new stake in CRISPR Therapeutics in the third quarter valued at about $277,000. B & T Capital Management DBA Alpha Capital Management lifted its position in CRISPR Therapeutics by 40.1% in the third quarter. B & T Capital Management DBA Alpha Capital Management now owns 46,149 shares of the company’s stock valued at $2,095,000 after purchasing an additional 13,208 shares during the period. Finally, Baker Chad R acquired a new stake in CRISPR Therapeutics in the third quarter valued at about $2,365,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.